A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings

This study is a secondary analysis of the Adelphi Real World Alopecia Areata II United States Disease Specific Programmes database. This database contains data from a cross-sectional study capturing linked physician and patient survey data for dermatologists who treat alopecia areata and patients diagnosed with alopecia areata in the United States. The retrospective analysis of these data will evaluate experiences of patients and dermatologists receiving/prescribing ritlecitinib for severe alopecia areata in the United States. Specifically, the study will describe characteristics of patients who received ritlecitinib for severe alopecia areata, including demographics, clinical characteristics at the time of starting ritlecitinib, and their alopecia areata-related treatment history. The study will also report dermatologist satisfaction with treatment and change in the patient's alopecia areata severity and disease activity from the start of ritlecitinib to different time points on treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Severe Alopecia Areata Alopecia Alopecia Areata Hair Diseases Hypotrichosis Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Pfizer

New York, 10001, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Aged 18 years or older with severe alopecia areata

Treatment and study plan

Ritlecitinib

Drug

As provided in real world practice

Primary outcomes

% of patients for whom their clinician was "satisfied" with current control of alopecia areata

Time frame: 11/15/2023 to 06/10/2024
% of patients with clinician-assessed mild, moderate, or severe disease

Time frame: 11/15/2023 to 06/10/2024
% of patients with clinician assessed progressive, stable, or improving disease

Time frame: 11/15/2023 to 06/10/2024

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Satisfaction and Treatment Experiences With RitlEcitiNib And Traditional Treatments for Severe Alopecia Areata Among Adults in the United States (SERENATA)

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Sep 30, 2025
Registry last updated: Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting